• mile米乐集团

    Global
    关于mile米乐集团

    致力于纳米抗体创新药物研发

    关于mile米乐集团
    科研论文
    截止现在，mile米乐集团生物研发团队在具有重要影响力的期刊上发表研究论文多篇。
    2022-06-08
    Nanobody-based label-free photoelectrochemical immunoassay for highly sensitive detection of SARS-CoV-2 spike protein
    发表于:Analytica chimica acta. 2022 Jun 8;1211:339904
    查看更多内容
    2022-01-11
    Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECTCT
    发表于:European Journal of Nuclear Medicine and Molecular Imaging. 2022 May;49(6):1810-1821
    查看更多内容
    2021-01-31
    A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential
    发表于:MedComm (2020). 2021 Mar;2(1):101-113
    查看更多内容
    2020-10-16
    Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
    发表于:Journal for ImmunoTherapy of Cancer. 2020 Nov;8(2):e001156
    查看更多内容
    2020-10-15
    A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade
    发表于:Biochemical and Biophysical Research Communications. 2020 Oct 15;531(2):144-151
    查看更多内容
    2020-02-15
    Evaluation of 64Cu radiolabeled anti-hPD-L1 Nb6 for positron emission tomography imaging in lung cancer tumor mice model
    发表于:Bioorganic & Medicinal Chemistry Letters. 2020 Feb 15;30(4):126915
    查看更多内容
    总计 24 1234